Current Report · Items 7.01, 9.01 · 8-K
Monogram Technologies Inc.
Regulation FD Disclosure
ITEM 7.01 REGULATION FD DISCLOSURE On July 29, 2025, Monogram Technologies Inc. (the “Company”) issued a press release (the “Press Release”) announcing that the Company performed the world’s first fully autonomous saw-based robotic knee replacement surgery. The procedure utilized the Company’s mBôs™ TKA System and was performed at the Krishna Shalby Hospital in Ahmedabad India.…
Filed Jul 29, 2025Accepted Jul 29, 2025, 5:31 AM EDTCIK 1769759Accession 0001104659-25-071470
Company context
Monogram Technologies (NASDAQ: MGRM) is an AI-driven robotics company focused on improving human health, with an initial focus on orthopedic surgery. The Company is developing a product solution architecture to enable patient-optimized orthopedic implants at scale by combining 3D printing, advanced machine vision, AI and next-generation robotics. To learn more, visit www.monogramtechnologies.com.
Historical securities (1)
Disclosure sections
Items 7.01, 9.01Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 7.01Item 7.01 - Regulation FD Disclosure
ITEM 7.01 REGULATION FD DISCLOSURE
On July 29, 2025, Monogram Technologies Inc. (the
“Company”) issued a press release (the “Press Release”) announcing that the Company performed the world’s
first fully autonomous saw-based robotic knee replacement surgery. The procedure utilized the Company’s mBôs™ TKA System
and was performed at the Krishna Shalby Hospital in Ahmedabad India.
The foregoing disclosure is qualified in its entirety
by the full text of the Press Release.
A copy of the Press Release is attached as Exhibit
99.1, and is hereby incorporated by reference into this Item 7.01. The information contained in this Current Report on Form 8-K, including
Exhibit 99.1 furnished herewith, is being furnished and shall not be deemed “filed” for any purpose, including for the purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities
of that Section and shall not be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933,
as amended, regardless of any general incorporation language in such filing, except to the extent expressly stated in such filing.
Cautionary Note Regarding Forward-Looking Statements
This Current Report on Form 8-K, including the
Press Release, contains forward-looking statements. Forward-looking statements reflect management's current knowledge, assumptions, judgment,
and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements
are reasonable, they give no assurance that such expectations will prove to be correct, and you should be aware that actual events or
results may differ materially from those contained in the forward- looking statements. Words such as "will," "expect,"
"intend," "plan," "potential," "possible," "goals," "accelerate," "continue,"
and similar expressions identify forward-looking statements.
Forward-looking statements are subject to a number
of risks and uncertainties including, but not limited to, the risks inherent in the Company’s lack of profitability and need for
additional capital to grow its business; the Company’s dependence on partners to further the development of its product candidates;
the uncertainties inherent in the development, attainment of the requisite regulatory authorizations and approvals and launch of any new
product; the outcome of pending or future litigation; and the various risks and uncertainties described in the "Risk Factors"
sections of the Company’s latest annual and quarterly reports and other filings with the SEC.
All forward-looking statements are expressly qualified
in their entirety by this cautionary notice. You should not rely upon any forward-looking statements as predictions of future events.
The Company undertakes no obligation to revise or update any forward-looking statements made in this Current Report on Form 8-K to reflect
events or circumstances after the date hereof, to reflect new information or the occurrence of unanticipated events, to update the reasons
why actual results could differ materially from those anticipated in the forward-looking statements, in each case, except as required
by law.
Filed exhibits (1)
EX-99.1 (by filename) tm2521919d1_ex99-1.htmEX-99.1
2
tm2521919d1_ex99-1.htm
EXHIBIT 99.1
Exhibit 99.1
Monogram Technologies Announces World’s
First Fully Autonomous Saw-Based Robotic Knee Replacement Surgery
The Procedure Utilized Monogram’s mBôs
TKA System Performed in India with Shalby Hospitals
Groundbreaking Procedure Delivers the World’s
First Autonomous Saw-Based Robotic TKA Surgery on a Live Patient
AUSTIN, TX - July 29, 2025 - Monogram Technologies Inc. (NASDAQ: MGRM) ("Monogram" or the "Company"), an AI-driven robotics company revolutionizing
orthopedic surgery, today announced that on Saturday, July 26, 2025, Monogram completed the first ever fully autonomous saw-based
robotic knee replacement procedure on a live patient.
The procedure was performed at the Krishna Shalby
Hospital in Ahmedabad India, as part of Monogram’s multi-center clinical trial in India for the Monogram TKA System.
As previously announced, Monogram and Shalby
partnered to evaluate the safety and effectiveness of the mBôs TKA System with the Consensus CKS implant, which is substantially
equivalent to the Monogram mPress implants for regulatory purposes. On April 29, 2025, Monogram obtained regulatory approval from
India's Central Drug…
Open exhibit ↗